Key result
Vasopeptidase inhibitors like omapatrilat show efficacy in treating hypertension and heart failure through dual ACE and NEP inhibition, though safety concerns regarding angioedema remain.
Why the study?
Do vasopeptidase inhibitors like omapatrilat effectively reduce blood pressure and provide cardioprotection in hypertension and heart failure compared to single-pathway inhibitors?
Do vasopeptidase inhibitors like omapatrilat effectively reduce blood pressure and provide cardioprotection in hypertension and heart failure compared to single-pathway inhibitors?
Vasopeptidase inhibitors such as omapatrilat offer a promising dual-mechanism approach for treating hypertension and heart failure, but their clinical advancement is hindered by the risk of angioedema.
No takes yet. Share an insight, caveat, or question.
May enhance BP lowering via dual ACE-NEP inhibition in animals; leaves open translation to human outcomes.
Nawarskas et al. (2001) conducted a review in Hypertension and heart failure. Vasopeptidase inhibitors (omapatrilat) was evaluated. Vasopeptidase inhibitors like omapatrilat show efficacy in treating hypertension and heart failure through dual ACE and NEP inhibition, though safety concerns regarding angioedema remain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: